1. Home
  2. ONC vs TDY Comparison

ONC vs TDY Comparison

Compare ONC & TDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONC
  • TDY
  • Stock Information
  • Founded
  • ONC 2010
  • TDY 1960
  • Country
  • ONC Switzerland
  • TDY United States
  • Employees
  • ONC N/A
  • TDY N/A
  • Industry
  • ONC Biotechnology: Pharmaceutical Preparations
  • TDY Industrial Machinery/Components
  • Sector
  • ONC Health Care
  • TDY Industrials
  • Exchange
  • ONC Nasdaq
  • TDY Nasdaq
  • Market Cap
  • ONC 31.5B
  • TDY 26.0B
  • IPO Year
  • ONC N/A
  • TDY 1999
  • Fundamental
  • Price
  • ONC $299.01
  • TDY $544.13
  • Analyst Decision
  • ONC Strong Buy
  • TDY Strong Buy
  • Analyst Count
  • ONC 9
  • TDY 7
  • Target Price
  • ONC $332.44
  • TDY $576.57
  • AVG Volume (30 Days)
  • ONC 411.4K
  • TDY 465.2K
  • Earning Date
  • ONC 08-06-2025
  • TDY 07-23-2025
  • Dividend Yield
  • ONC N/A
  • TDY N/A
  • EPS Growth
  • ONC N/A
  • TDY N/A
  • EPS
  • ONC N/A
  • TDY 18.14
  • Revenue
  • ONC $4,175,868,000.00
  • TDY $5,909,400,000.00
  • Revenue This Year
  • ONC $865.19
  • TDY $7.88
  • Revenue Next Year
  • ONC $21.12
  • TDY $5.51
  • P/E Ratio
  • ONC N/A
  • TDY $29.95
  • Revenue Growth
  • ONC 51.16
  • TDY 6.44
  • 52 Week Low
  • ONC $155.75
  • TDY $397.78
  • 52 Week High
  • ONC $308.87
  • TDY $570.56
  • Technical
  • Relative Strength Index (RSI)
  • ONC N/A
  • TDY 56.87
  • Support Level
  • ONC N/A
  • TDY $545.57
  • Resistance Level
  • ONC N/A
  • TDY $560.13
  • Average True Range (ATR)
  • ONC 0.00
  • TDY 13.50
  • MACD
  • ONC 0.00
  • TDY -1.85
  • Stochastic Oscillator
  • ONC 0.00
  • TDY 48.51

About ONC BeiGene Ltd. American Depositary Shares

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

About TDY Teledyne Technologies Incorporated

Teledyne Technologies Inc sells technologies for industrial markets. Roughly a fourth of Teledyne's revenue comes from contracts with the United States government. The firm operates in four segments: instrumentation, digital imaging, aerospace and defense electronics, and engineered systems. The instrumentation segment provides monitoring instruments primarily for marine and environmental applications. The digital imaging segment contributes majority of proportion of revenue and includes image sensors and cameras for industrial, government, and medical customers. The aerospace and defense electronics segment provides electronic components and communication products for aircraft. The engineered systems segment provides solutions for defense, space, environmental, and energy applications.

Share on Social Networks: